<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2066832A-702C-4D9C-B26C-1C0EF4581A30"><gtr:id>2066832A-702C-4D9C-B26C-1C0EF4581A30</gtr:id><gtr:name>Oxford BioMedica UK Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A23AF92A-1022-47A0-9EC7-7B636A203B19"><gtr:id>A23AF92A-1022-47A0-9EC7-7B636A203B19</gtr:id><gtr:name>Renishaw Plc</gtr:name><gtr:address><gtr:line1>New Mills</gtr:line1><gtr:line4>Wotton-under-Edge</gtr:line4><gtr:line5>Gloucestershire</gtr:line5><gtr:postCode>GL12 8JR</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E021FE18-3AEE-466F-B84A-5EA20421F1D7"><gtr:id>E021FE18-3AEE-466F-B84A-5EA20421F1D7</gtr:id><gtr:name>Hermo Pharma</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/62B693D8-12F4-4EEE-A622-010188252868"><gtr:id>62B693D8-12F4-4EEE-A622-010188252868</gtr:id><gtr:name>North Bristol NHS Trust</gtr:name><gtr:department>Directorate of Neurosciences</gtr:department><gtr:address><gtr:line1>Trust Headquarters</gtr:line1><gtr:line2>Frenchay Hospital</gtr:line2><gtr:line3>Beckspool Road, Frenchay</gtr:line3><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS16 1JE</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/62B693D8-12F4-4EEE-A622-010188252868"><gtr:id>62B693D8-12F4-4EEE-A622-010188252868</gtr:id><gtr:name>North Bristol NHS Trust</gtr:name><gtr:address><gtr:line1>Trust Headquarters</gtr:line1><gtr:line2>Frenchay Hospital</gtr:line2><gtr:line3>Beckspool Road, Frenchay</gtr:line3><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS16 1JE</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2066832A-702C-4D9C-B26C-1C0EF4581A30"><gtr:id>2066832A-702C-4D9C-B26C-1C0EF4581A30</gtr:id><gtr:name>Oxford BioMedica UK Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A23AF92A-1022-47A0-9EC7-7B636A203B19"><gtr:id>A23AF92A-1022-47A0-9EC7-7B636A203B19</gtr:id><gtr:name>Renishaw Plc</gtr:name><gtr:address><gtr:line1>New Mills</gtr:line1><gtr:line4>Wotton-under-Edge</gtr:line4><gtr:line5>Gloucestershire</gtr:line5><gtr:postCode>GL12 8JR</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E021FE18-3AEE-466F-B84A-5EA20421F1D7"><gtr:id>E021FE18-3AEE-466F-B84A-5EA20421F1D7</gtr:id><gtr:name>Hermo Pharma</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7807E7B0-0709-4728-B283-5B83F76D0B5D"><gtr:id>7807E7B0-0709-4728-B283-5B83F76D0B5D</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:surname>Gill</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601745"><gtr:id>71D6AA53-76A5-4DBA-A293-AEEE56787EC8</gtr:id><gtr:title>The development of innovative techniques for controlled drug delivery to the central nervous system</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601745</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The blood-brain barrier represents a considerable hurdle to the delivery of drugs to the nervous
system. We propose to develop innovative techniques to bypass this barrier that could
revolutionise the management of numerous neurological diseases.
Convection-enhanced delivery (CED) utilises extremely fine intracranial catheters and low infusion rates to impart drugs directly into the brain extracellular space. In contrast to direct
intraparenchymal injection, encapsulated cells and biodegradeable polymers, CED does not
depend on diffusion. The use of a carefully designed cannula with a precisely controlled infusion
rate leads to the development of a pressure gradient, along which drug passes directly into the
extracellular space. Consequently, unlike diffusion, it is possible to achieve controlled,
homogeneous drug distribution, regardless of drug molecular size, over large volumes of the
brain.
The principal limitation of CED is that the distribution of drugs through the extracellular space can
be unpredictable. The key factors affecting drug distribution by CED are catheter design and site
of placement, infusion flow-rate, drug charge and non-specific drug binding. At present, although
there are a number of clinical trials attempting to administer drugs using this technique, there are
no commercially available catheters that have been designed to tackle these issues, and indeed
the available evidence suggests that the catheters in use are incompatible with successful CED.
We propose to develop a versatile, stereotactically inserted drug delivery system, with associated software, that is capable of delivering neurotrophic proteins, as well as liposomal and viral vectormediated gene therapy and RNA interference in a controlled and predictable manner. The use of synthetic brain models and post-mortem brain specimens would allow evaluation of novel catheter designs, insertion techniques, coinfusion agents and infusion parameters and discourage the use of primates in the modelling of CED.
Aside from the optimisation of CED we propose to evaluate entirely novel concepts that may
dramatically improve drug delivery. We intend to utilise available knowledge on safe current
application to the brain, derived from the technique of deep brain stimulation (DBS), to improve
drug delivery. As proteins, liposomes and viruses typically possess an intrinsic charge, it should
be possible to achieve ?steerable? drug movement through the brain, in a comparable approach
to transdermal iontophoresis. This would be particularly relevant in the safe delivery of gene
therapy or RNA interference in which gene expression or repression is required in tightly
controlled anatomical structures.
This research represents innovative, but high-risk research. We will be working closely with a
number of researchers to optimise the delivery of novel therapeutic agents, including
neurotrophic factors for Parkinson?s disease, RNA interference for Huntington?s disease and
hereditary ataxias, as well as oncolytic viruses for brain tumours. The development of an efficient drug delivery system capable of precisely controlled delivery of these agents has the potential to revolutionise the management of these conditions and is ideal for Milstein funding.</gtr:technicalSummary><gtr:fund><gtr:end>2009-06-14</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-12-15</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>300000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amgen Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Biovex</gtr:department><gtr:description>HSV</gtr:description><gtr:id>977E4D75-11B1-4D09-8301-4AFE4AF0208C</gtr:id><gtr:impact>Publication due for submission Jan, 2010.</gtr:impact><gtr:outcomeId>2C68B17F050-1</gtr:outcomeId><gtr:partnerContribution>Provision of herpes simplex-1 based viral vectors for testing in vivo.</gtr:partnerContribution><gtr:piContribution>We have evaluated and optimised the administration of HSV-1-based viral vectors by convection-enhanced delivery in both small and large animal models.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford BioMedica UK Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EIAV</gtr:description><gtr:id>4ECEE62F-1C9C-4696-B03E-22662750A843</gtr:id><gtr:impact>Publication due for submission Jan, 2010.</gtr:impact><gtr:outcomeId>1A346494E40-1</gtr:outcomeId><gtr:partnerContribution>Provision of lentiviral vectors for testing in animal models.</gtr:partnerContribution><gtr:piContribution>We have evaluated and optimised the administration of lentiviral vectors by convection-enhanced delivery in both small and large animal models.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Renishaw plc</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Surgical Equipment</gtr:description><gtr:id>E2F3F964-F296-4885-A601-401346D9718F</gtr:id><gtr:impact>Collaboration with medical engineering company to develop drug delivery equipment for use in humans.</gtr:impact><gtr:outcomeId>589B70A8E12-1</gtr:outcomeId><gtr:partnerContribution>Renishaw have provided stereotactic surgical equipment that have allowed us to undertake experiments in large animals.</gtr:partnerContribution><gtr:piContribution>We have evaluated their drug delivery equipment in large animal models.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Computer Science</gtr:department><gtr:description>Diffusion imaging</gtr:description><gtr:id>24137D3E-6935-4206-8059-C67B8B8E3E88</gtr:id><gtr:impact>Mathematical models have been developed in an attempt to visualise the brain extracellular space. These are currently being tested. Tractography atlases of rat and pig brain have also been developed.</gtr:impact><gtr:outcomeId>E3BBC4B91ED-1</gtr:outcomeId><gtr:partnerContribution>This collaboration has allowed us to optimise the MR imaging performed in our preclinical studies.</gtr:partnerContribution><gtr:piContribution>We initiated a project and provided the raw data to undertake studies attempting to use diffusion imaging to predict drug distribution in the brain.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>AAV</gtr:description><gtr:id>43AB3C8E-EB54-4E50-AAA7-10E8B04CC6AA</gtr:id><gtr:impact>Plans to conduct a gene therapy trial for Tay-Sachs disease in 2012.</gtr:impact><gtr:outcomeId>A64C7ED58BA-1</gtr:outcomeId><gtr:partnerContribution>Provision of viral vectors for testing in animal models.</gtr:partnerContribution><gtr:piContribution>We have evaluated and optimised the administration of recombinant adeno-associated viral vectors by convection-enhanced delivery in both small and large animal models.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>Nanoparticle Project</gtr:description><gtr:id>9B5318C5-5A07-488F-BB76-2072C5A91F45</gtr:id><gtr:impact>Publication due for submission December 2009.</gtr:impact><gtr:outcomeId>474AEFA4829-1</gtr:outcomeId><gtr:partnerContribution>Provision of receptor-targeted, MRI-visible nanoparticles for testing in animal models.</gtr:partnerContribution><gtr:piContribution>We evaluated the ability of these nanoparticles to transduce cells in vivo. In addition we examined the immune responses directed against these nanoparticles when infused into the brain.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hermo Pharma</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>Pre-clinical CDNF Distrubution Studies</gtr:description><gtr:id>B0126565-9D20-4A1A-8A48-961F1752D0DA</gtr:id><gtr:impact>Knowledge to aid Large preclinical and clinical trials.</gtr:impact><gtr:outcomeId>Cwi8ny6c2XZ-1</gtr:outcomeId><gtr:partnerContribution>The purpose of this study is assess the distribution infused CDNF in order for clinical studies to occur in the future</gtr:partnerContribution><gtr:piContribution>Research partners</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Mathematics</gtr:department><gtr:description>Mathematical Modelling</gtr:description><gtr:id>CFADBD1F-B4DF-4AB9-AC10-8702CA54B0C9</gtr:id><gtr:impact>This collaboration has led to the development of a mathematical model of drug distribution by convection-enhanced delivery. We are in the process of testing this model in vivo.</gtr:impact><gtr:outcomeId>D27AE36E669-1</gtr:outcomeId><gtr:piContribution>We initiated this project and supplied raw data for our collaborators to develop mathematical models of drug distribution through the brain.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>World Society for Stereotactic and Functional Neurosurgery</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>312822FD-7B93-4F37-BD13-422478B67163</gtr:id><gtr:impact>I gave a talk to health care professionals regarding the development of methods of drug delivery to the brain for the treatment for a range of neurological diseases.

Nil.</gtr:impact><gtr:outcomeId>F2B1466A162</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference  (2015)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8A8960E5-8C0E-4F81-9531-FCEAE99F5F4F</gtr:id><gtr:impact>Surgical Modification of Neurodegenerative Disorders Dementia-HIT Research Showcase, University of Bristol

Knowledge sharing of CED to other researchers</gtr:impact><gtr:outcomeId>56e13f9a531512.34401605</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Friends of Bristol Haematology and Oncology Centre</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>74053DF4-AF53-4135-B108-574490D5EB09</gtr:id><gtr:impact>I gave a talk to patients with cancer and members of the public with regard to the development of techniques to administer drugs to the brain.

This meeting led to a significant donation to support our research.</gtr:impact><gtr:outcomeId>F902649E667</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>South-West Oncology Study Day</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EEC43E3F-9562-41C2-8B85-101305920E82</gtr:id><gtr:impact>Talks were given to health care professionals involved in the care of patients with brain tumours, with regard to experimental treatment strategies to manage these patients.

This talk led to financial donations being given to further this project.</gtr:impact><gtr:outcomeId>B51767D139B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Society of Medicine</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E9590DAD-2C4F-402E-BE92-26FE320D53AB</gtr:id><gtr:impact>I gave a talk to health care professionals regarding the development of novel therapies for Parkinson's disease, based on direct intracranial delivery of neurotrophic agents.

Nil.</gtr:impact><gtr:outcomeId>C7CF8564308</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Paediatric Neurology Association 2006 Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D627DFA1-2CC3-46C6-9BE6-CDFA739B2D96</gtr:id><gtr:impact>I gave a talk on the future surgical therapies for paediatric movement disorders to paediatric neurologists nationally.

Nil.</gtr:impact><gtr:outcomeId>92D4A25829E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neuromodulation Symposium (Budapest)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EDE6EAD9-AC78-45DA-A7A7-6A0928443A31</gtr:id><gtr:impact>I gave a talk to health care professionals, members of the medical device industry and the public on the subject of techniques of drug delivery to the brain for the treatment of movement disorders.

Nil.</gtr:impact><gtr:outcomeId>A3F363CBBE6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GDNF Phase II Study Planning Meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1E21B514-F5F3-43DC-97FC-86D9ACC69EA1</gtr:id><gtr:impact>A number of company, health professionals and researcher involved in the collaboration

Engagement in the role of all interested parties</gtr:impact><gtr:outcomeId>BhomPGFUbST</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>3rd International Symposium on Convention Enhanced Delivery to the Brain</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3A581429-25A8-4452-AC90-0ECCD797D6D4</gtr:id><gtr:impact>3rd International Symposium on Convention Enhanced Delivery to the Brain

I gave a talk with regard to our experiences with techniques of direct intracranial drug delivery.</gtr:impact><gtr:outcomeId>8977F183BD9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Bristol Medico-Chirurgical Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A53A6DA3-D7ED-48F1-B551-1D8D2D45E1BC</gtr:id><gtr:impact>I gave a talk on techniques of drug delivery to the brain for the treatment of a range of neurological diseases.

Nil.</gtr:impact><gtr:outcomeId>75E8E9B59B9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>First Hammer Out Patient/Carer Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9F71FBDC-3322-43C3-887A-07589289B535</gtr:id><gtr:impact>I gave a talk to patients and carers of patients with primary brain tumours regarding our research into new techniques and treatments for brain tumours.

Nil.</gtr:impact><gtr:outcomeId>76D9377F81D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neurological Society of Australasia, Auckland</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E832EADC-5982-4A33-B95C-A80E575D42B5</gtr:id><gtr:impact>I gave a talk to health care professionals regarding the development of novel therapies for Parkinson's disease, based on direct intracranial delivery of neurotrophic agents.

Nil.</gtr:impact><gtr:outcomeId>7D50EBF86B7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Blood-Brain Barrier Consortium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>38E028CF-8A79-46C2-9FF4-C0E5BA09C0E8</gtr:id><gtr:impact>Gave a talk to a consortium of health care professionals involved in caring for patients with lysosomal storage diseases.

This talk led to discussions regarding future treatment strategies that could be employed to treat the neurological complications of lysosomal storage diseases. These discussions may lead to clinical trials being initiated.</gtr:impact><gtr:outcomeId>56E461BC2B1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCRI - Brain Tumour Technology Subgroup Committee</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E40D3CD7-37B6-4C8A-9FBE-A71762D8A606</gtr:id><gtr:impact>I presented evidence to the NRCI Brain Tumour Technology Subgroup Committee regarding techniques of drug delivery to patients with brain tumours. I specifically discussed the technique of convection-enhanced delivery.

This committee is now seeking to develop and support a phase I/II study of convection-enhanced delivery of conventional chemotherapeutic agents in the management of patients with high-grade gliomas.</gtr:impact><gtr:outcomeId>4848815F0B6</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Minneapolis</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FFAD9191-524A-49EE-A040-64BD58C517B2</gtr:id><gtr:impact>I gave a talk on the surgical management of movement disorders to health care professionals and members of the medical devices industry.

Nil.</gtr:impact><gtr:outcomeId>D98F6EDC24D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference (2015) Ireland</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>81296289-B02F-4185-BA80-E3B0365E66DA</gtr:id><gtr:impact>Nov 2015 Robot-assisted Deep Brain Stimulation for Pain Neuromodulation Society of the UK and Ireland, London, UK</gtr:impact><gtr:outcomeId>56e13ffe4aa011.91778379</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>21195</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Nanotechnology for Healthcare EP/G061831/1 Nanoparticles for the Targeted Delivery of Therapeutic Agents to the Brain for the Treatment of Dementias</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/G061831/1</gtr:fundingRef><gtr:id>768F809F-98A2-47AD-A6EF-F17BE7D2B061</gtr:id><gtr:outcomeId>F5A4A5A4A160</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC MR/J005134/1. Convection-enhanced delivery of encapsulated nanosperes for controlled delivery of chemotherapy to the brain</gtr:description><gtr:end>2013-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D6C24CED-1400-4CA9-A656-08CA75F12590</gtr:id><gtr:outcomeId>SbCoU9uWLiN0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Inductively coupled plasma mass spectrometry (ICP-MS) is a type of mass spectrometry which is capable of detecting metals and several non-metals at concentrations as low as one part in 1012 (part per trillion). Used .for ongoing projects in collaboration with Sheffield university</gtr:description><gtr:id>0EEDC6A2-1660-4AE6-AF18-E7FB3486D5D5</gtr:id><gtr:impact>Excellent quantitative results obtained.</gtr:impact><gtr:outcomeId>LjDPNthidWF</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ICP-MS</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>934383FA-D8EF-45B1-AB9D-06949C1207AF</gtr:id><gtr:title>The development of an implantable catheter system for chronic or intermittent convection-enhanced delivery.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6559dcd9ed29268aa48032f3051c2fed"><gtr:id>6559dcd9ed29268aa48032f3051c2fed</gtr:id><gtr:otherNames>Bienemann A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn><gtr:outcomeId>spy8jAAuM9o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>270D32C0-A0F2-40FE-80A3-51F5EA5C5BF4</gtr:id><gtr:title>A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme.</gtr:title><gtr:parentPublicationTitle>Contemporary clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bf35c02b678f95ce3832966880e6f44"><gtr:id>5bf35c02b678f95ce3832966880e6f44</gtr:id><gtr:otherNames>White E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1551-7144</gtr:issn><gtr:outcomeId>pm_16323_23_22101221</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C01A0C7C-C43E-4DE5-82D7-FA6223196513</gtr:id><gtr:title>Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model.</gtr:title><gtr:parentPublicationTitle>International journal of nanomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/672472503ff42235b331a15f3ba9b375"><gtr:id>672472503ff42235b331a15f3ba9b375</gtr:id><gtr:otherNames>Singleton WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1176-9114</gtr:issn><gtr:outcomeId>58c7d772cef792.33501388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B0D8B22-F666-4E1B-A085-E92C342D864C</gtr:id><gtr:title>An evaluation of the relationships between catheter design and tissue mechanics in achieving high-flow convection-enhanced delivery.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bf35c02b678f95ce3832966880e6f44"><gtr:id>5bf35c02b678f95ce3832966880e6f44</gtr:id><gtr:otherNames>White E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn><gtr:outcomeId>jQqTQUDw3k2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FDA2363-8A93-4F5E-AED7-174CD6FD1D68</gtr:id><gtr:title>Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6f4e9cea913b477edebe9457cdfb5bc"><gtr:id>a6f4e9cea913b477edebe9457cdfb5bc</gtr:id><gtr:otherNames>Killick-Cole CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5aa7bd277d80a8.72596473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C89B0F35-430E-4EED-A677-D1B8131531AB</gtr:id><gtr:title>Multifunctional receptor-targeted nanocomplexes for the delivery of therapeutic nucleic acids to the brain.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36d7eecaa60f348d6b1c3ec6e2ee1466"><gtr:id>36d7eecaa60f348d6b1c3ec6e2ee1466</gtr:id><gtr:otherNames>Kenny GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn><gtr:outcomeId>pm_16323_23_23948162</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0434D1F7-C15A-4B27-B265-A469EE3E9984</gtr:id><gtr:title>Distribution properties of lentiviral vectors administered into the striatum by convection-enhanced delivery.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bf35c02b678f95ce3832966880e6f44"><gtr:id>5bf35c02b678f95ce3832966880e6f44</gtr:id><gtr:otherNames>White E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>aFTNb8UjkqM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70B620C0-5E64-41FD-8D19-EABCD56B477A</gtr:id><gtr:title>Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery.</gtr:title><gtr:parentPublicationTitle>Cancer gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bf35c02b678f95ce3832966880e6f44"><gtr:id>5bf35c02b678f95ce3832966880e6f44</gtr:id><gtr:otherNames>White E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0929-1903</gtr:issn><gtr:outcomeId>a14Re7kkEYT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B5709E0-5DF2-4F8B-AC59-FBC3DB44E6CB</gtr:id><gtr:title>Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains.</gtr:title><gtr:parentPublicationTitle>American journal of translational research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff7aa49de9168b62f11f95bc6701619d"><gtr:id>ff7aa49de9168b62f11f95bc6701619d</gtr:id><gtr:otherNames>Tsujiuchi T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54624bac3b5321.99333393</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77706059-E2D1-4FB6-BEB5-06B03991D376</gtr:id><gtr:title>A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma.</gtr:title><gtr:parentPublicationTitle>Drug delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46a353232dc6e1939e713f411c4236f4"><gtr:id>46a353232dc6e1939e713f411c4236f4</gtr:id><gtr:otherNames>Barua NU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1071-7544</gtr:issn><gtr:outcomeId>54624bac712647.33585174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2CE9C13-2718-4B67-9E24-D07C26538D85</gtr:id><gtr:title>Evaluation and optimization of the administration of recombinant adeno-associated viral vectors (serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by convection-enhanced delivery to the striatum.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bf35c02b678f95ce3832966880e6f44"><gtr:id>5bf35c02b678f95ce3832966880e6f44</gtr:id><gtr:otherNames>White E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>PXVyRPTikDD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5BBE76A-6504-41A4-A5A9-E50B1219BD9F</gtr:id><gtr:title>An evaluation of site-specific immune responses directed against first-generation adenoviral vectors administered by convection-enhanced delivery.</gtr:title><gtr:parentPublicationTitle>The journal of gene medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bf35c02b678f95ce3832966880e6f44"><gtr:id>5bf35c02b678f95ce3832966880e6f44</gtr:id><gtr:otherNames>White E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1099-498X</gtr:issn><gtr:outcomeId>TtYDH7ixYrE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD99A2E4-0A3E-4B2D-956D-2C1F2799E3D9</gtr:id><gtr:title>A robust MRI-compatible system to facilitate highly accurate stereotactic administration of therapeutic agents to targets within the brain of a large animal model.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bf35c02b678f95ce3832966880e6f44"><gtr:id>5bf35c02b678f95ce3832966880e6f44</gtr:id><gtr:otherNames>White E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn><gtr:outcomeId>sWojyC4wTLX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>696940A4-767B-4E5B-8850-CF42BD9196B9</gtr:id><gtr:title>Lipid peptide nanocomplexes for gene delivery and magnetic resonance imaging in the brain.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f208c20ac8f62f477b98e922c877258a"><gtr:id>f208c20ac8f62f477b98e922c877258a</gtr:id><gtr:otherNames>Writer MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>pm_16323_23_22800579</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601745</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>